Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: Focus on LUX-Lung 3 and LUX-Lung 6 phase III trials

Journal of Thoracic Disease

Volumn 5, Issue 4, 2013, Pages 383-384

  Passaro, Antonio ^a   Gori, Bruno ^a   de Marinis, Filippo ^a  

^a High Spcializazion Hospital   (Italy)

Author keywords

Afatinib; Epithelial growth factor receptor (EGFR); Non small cell lung cancer (NSCLC); Tyrosine kinase inhibitor (TKI)

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PEMETREXED;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; EDITORIAL; GENE DELETION; GENE MUTATION; HUMAN; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MEDIAN SURVIVAL TIME; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 84905652225     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.07.32     Document Type: Editorial

References (9)

1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
2. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
4. Inoue A, Kobayashi K, Maemondo M, et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. J Clin Oncol 2011;29:7519.
5. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-8.
6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
7. Sequist LV, Yang JC, Yamamoto N, et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 2013. [Epub ahead of print].
8. ClinicalTrials.gov. BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-Small Cell Lung Cancer (NSCLC). NCT01121393. Available online: http://clinicaltrials.gov/show/NCT01121393, accessed July 10, 2013.
9. Yang JC, Hirsh V, Schuler M, et al. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 2013. [Epub ahead of print].